Cabozantinib versus other TKIs after CPI treatment in the real-world management of patients with mRCC.
JOURNAL OF CLINICAL ONCOLOGY(2021)
摘要
293Background: Checkpoint inhibitors (CPIs) are a treatment option for patients with metastatic renal cell carcinoma (mRCC), but there is limited clinical data on the efficacy of targeted therapies...
更多查看译文
关键词
metastatic renal cell carcinoma,cpi treatment,cell carcinoma,real-world
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要